Novo Nordisk
NVO
#110
Rank
NZ$322.91 B
Marketcap
NZ$73.25
Share price
-1.07%
Change (1 day)
-17.55%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): NZ$6.88

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is NZ$7.11. In 2025 the company made an earnings per share (EPS) of NZ$6.40 an increase over its 2024 EPS that were of NZ$5.90.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.887.59%
2025NZ$6.408.48%
2024NZ$5.90
2016NZ$2.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.28-82.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$55.67 682.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.57-49.81%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
NZ$8.15 14.55%๐Ÿ‡บ๐Ÿ‡ธ USA